MX2022003010A - Tratamiento de la emr mediante cambio de terapia. - Google Patents
Tratamiento de la emr mediante cambio de terapia.Info
- Publication number
- MX2022003010A MX2022003010A MX2022003010A MX2022003010A MX2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- therapy
- emr
- change
- ofatumumab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196789 | 2019-09-11 | ||
| EP20154736 | 2020-01-30 | ||
| PCT/EP2020/075332 WO2021048280A1 (en) | 2019-09-11 | 2020-09-10 | Treatment of rms by switching therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003010A true MX2022003010A (es) | 2022-06-02 |
Family
ID=72709332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003010A MX2022003010A (es) | 2019-09-11 | 2020-09-10 | Tratamiento de la emr mediante cambio de terapia. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220298253A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3864053B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7794735B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220062025A (cg-RX-API-DMAC7.html) |
| CN (3) | CN118436777A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020344154A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150947A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3864053T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2957112T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3864053T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290619A (cg-RX-API-DMAC7.html) |
| LT (1) | LT3864053T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022003010A (cg-RX-API-DMAC7.html) |
| SI (1) | SI3864053T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021048280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4252847A3 (en) | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| WO2021204994A1 (en) * | 2020-04-09 | 2021-10-14 | Novartis Ag | Ofatumumab for treating ms while maintaining serum igg |
| CA3215371A1 (en) * | 2021-04-13 | 2022-10-20 | Shibeshih Mitiku BELACHEW | Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome |
| CN117529336A (zh) * | 2021-04-14 | 2024-02-06 | 诺华股份有限公司 | 用于治疗亚洲患者的多发性硬化症的奥法木单抗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| HK1231413A1 (zh) * | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| EP4252847A3 (en) * | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
-
2020
- 2020-09-10 JP JP2022515966A patent/JP7794735B2/ja active Active
- 2020-09-10 US US17/753,632 patent/US20220298253A1/en active Pending
- 2020-09-10 LT LTEPPCT/EP2020/075332T patent/LT3864053T/lt unknown
- 2020-09-10 EP EP20785440.7A patent/EP3864053B1/en active Active
- 2020-09-10 ES ES20785440T patent/ES2957112T3/es active Active
- 2020-09-10 AU AU2020344154A patent/AU2020344154A1/en active Pending
- 2020-09-10 CN CN202410529206.7A patent/CN118436777A/zh active Pending
- 2020-09-10 CN CN202080064158.9A patent/CN114401742B/zh active Active
- 2020-09-10 CN CN202410529209.0A patent/CN118403156A/zh active Pending
- 2020-09-10 DK DK20785440.7T patent/DK3864053T3/da active
- 2020-09-10 FI FIEP20785440.7T patent/FI3864053T3/fi active
- 2020-09-10 CA CA3150947A patent/CA3150947A1/en active Pending
- 2020-09-10 SI SI202030263T patent/SI3864053T1/sl unknown
- 2020-09-10 EP EP23183390.6A patent/EP4230655A3/en active Pending
- 2020-09-10 KR KR1020227011366A patent/KR20220062025A/ko not_active Ceased
- 2020-09-10 WO PCT/EP2020/075332 patent/WO2021048280A1/en not_active Ceased
- 2020-09-10 MX MX2022003010A patent/MX2022003010A/es unknown
-
2022
- 2022-02-14 IL IL290619A patent/IL290619A/en unknown
-
2025
- 2025-09-25 JP JP2025159217A patent/JP2026016387A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020344154A1 (en) | 2022-04-07 |
| EP4230655A2 (en) | 2023-08-23 |
| CN114401742A (zh) | 2022-04-26 |
| CN118403156A (zh) | 2024-07-30 |
| EP3864053B1 (en) | 2023-07-05 |
| DK3864053T3 (da) | 2023-09-11 |
| JP2026016387A (ja) | 2026-02-03 |
| LT3864053T (lt) | 2023-09-11 |
| CN114401742B (zh) | 2024-05-24 |
| SI3864053T1 (sl) | 2023-12-29 |
| CN118436777A (zh) | 2024-08-06 |
| US20220298253A1 (en) | 2022-09-22 |
| IL290619A (en) | 2022-04-01 |
| CA3150947A1 (en) | 2021-03-18 |
| KR20220062025A (ko) | 2022-05-13 |
| EP4230655A3 (en) | 2023-11-01 |
| JP7794735B2 (ja) | 2026-01-06 |
| FI3864053T3 (fi) | 2023-09-13 |
| EP3864053A1 (en) | 2021-08-18 |
| WO2021048280A1 (en) | 2021-03-18 |
| JP2022548575A (ja) | 2022-11-21 |
| ES2957112T3 (es) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022000231A2 (pt) | Novos métodos | |
| MX2021002322A (es) | Nuevos metodos. | |
| DOP2019000241A (es) | ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| MX2021013974A (es) | Metodos, sistemas y dispositivos de seleccion de pacientes tl1a. | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
| EP4327866A3 (en) | Mirikizumab in the treatment of ulcerative colitis | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
| CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2025013942A (es) | Anticuerpos contra mucina 16 y metodos de uso de los mismos | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| BR112017022653A2 (pt) | ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph? | |
| EP4230655A3 (en) | Treatment of rms by switching therapy | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2021002761A (es) | Metodos para tratar la pancreatitis. | |
| CL2022000790A1 (es) | Método para tratar vih con cabotegravir y rilpivirina |